Pikralida sp. Z o.o. signed with the Board of the Wielkopolska Region, acting as the Managing Authority of the Wielkopolska Regional Operational Program for 2014-2020, a contract for co-financing the Project entitled Establishment of an R&D laboratory for supergeneric drugs no. RPWP.01.02.00-30- 0047 / 19-00 [JL1].
Co-financing was granted under Priority Axis 1 “Innovative and competitive economy”, Measure 1.2 “Strengthening the innovative potential of enterprises in Wielkopolska” of the Wielkopolska Regional Operational Program for 2014-2020.
The aim of the project is to produce a prototype of a formulation of a modern antidiabetic drug containing an active pharmaceutical substance in an amorphous form. As a result of the project, the beneficiary will develop new services that will expand its offer, i.e. the development of technologies for the amorphization of active pharmaceutical substances using the hot extrusion process and the development of drug formulations containing active pharmaceutical substances in amorphous form, and will improve the service consisting in the development of analytical methods.
Project implementation period: 01/10/2019 – 30/06/2021
Total value of the project: PLN 1,972,710.00
Co-financing of the project from the EU: PLN 1,260,200.00
Design logos
[JL1] [JL1]Tu przekierowanie do podstrony dedykowanej projektowi.